Drug-development, dose-selection, rational combinations from bench-to-bedside: are there any lessons worth revisiting?

One of the most intractable problems in drug development is getting an impartial and accurate evaluation of the agent one is working on, especially since patients are involved in clinical trials.It is particularly acute in the oncology field, where both cause and appropriate treatment of a tumor may partially be rational guesswork.In this situation, patients have a high likelihood of a sub-optimal outcome, notably when they, as profoundly...